Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 EPS estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.15) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $0.20 EPS.
ESPR has been the subject of a number of other reports. Cantor Fitzgerald began coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective for the company. JMP Securities reissued a "market outperform" rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. StockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics presently has an average rating of "Hold" and an average price target of $6.75.
Read Our Latest Analysis on Esperion Therapeutics
Esperion Therapeutics Stock Performance
Shares of Esperion Therapeutics stock traded down $0.03 on Friday, hitting $1.55. The company's stock had a trading volume of 9,000,067 shares, compared to its average volume of 4,207,690. The company has a market capitalization of $305.40 million, a price-to-earnings ratio of -2.42 and a beta of 1.04. Esperion Therapeutics has a 1 year low of $1.50 and a 1 year high of $3.94. The firm has a fifty day moving average price of $1.95 and a 200-day moving average price of $2.09.
Institutional Trading of Esperion Therapeutics
A number of hedge funds have recently bought and sold shares of ESPR. Wasatch Advisors LP grew its position in shares of Esperion Therapeutics by 4.9% in the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock valued at $53,861,000 after purchasing an additional 1,136,245 shares in the last quarter. Geode Capital Management LLC lifted its position in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company's stock worth $7,148,000 after buying an additional 171,609 shares in the last quarter. State Street Corp boosted its stake in Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company's stock worth $6,360,000 after buying an additional 99,802 shares during the last quarter. Two Sigma Advisers LP grew its holdings in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after buying an additional 16,100 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock worth $6,862,000 after acquiring an additional 1,020,243 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.
About Esperion Therapeutics
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
